JP5406725B2 - タンパク質キナーゼ阻害剤として有用な化合物 - Google Patents

タンパク質キナーゼ阻害剤として有用な化合物 Download PDF

Info

Publication number
JP5406725B2
JP5406725B2 JP2009541404A JP2009541404A JP5406725B2 JP 5406725 B2 JP5406725 B2 JP 5406725B2 JP 2009541404 A JP2009541404 A JP 2009541404A JP 2009541404 A JP2009541404 A JP 2009541404A JP 5406725 B2 JP5406725 B2 JP 5406725B2
Authority
JP
Japan
Prior art keywords
aliphatic
cancer
compound
halo
independently
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2009541404A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010513285A5 (OSRAM
JP2010513285A (ja
Inventor
ジャン・ダミアン・シャリエール
デイビッド・ケイ
ロナルト・クネフテル
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vertex Pharmaceuticals Inc
Original Assignee
Vertex Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vertex Pharmaceuticals Inc filed Critical Vertex Pharmaceuticals Inc
Publication of JP2010513285A publication Critical patent/JP2010513285A/ja
Publication of JP2010513285A5 publication Critical patent/JP2010513285A5/ja
Application granted granted Critical
Publication of JP5406725B2 publication Critical patent/JP5406725B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D475/00—Heterocyclic compounds containing pteridine ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Oncology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Communicable Diseases (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Transplantation (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Virology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Emergency Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2009541404A 2006-12-14 2007-12-14 タンパク質キナーゼ阻害剤として有用な化合物 Expired - Fee Related JP5406725B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US87487806P 2006-12-14 2006-12-14
US60/874,878 2006-12-14
PCT/US2007/025688 WO2008076392A2 (en) 2006-12-14 2007-12-14 Compounds useful as protein kinase inhibitors

Publications (3)

Publication Number Publication Date
JP2010513285A JP2010513285A (ja) 2010-04-30
JP2010513285A5 JP2010513285A5 (OSRAM) 2011-04-14
JP5406725B2 true JP5406725B2 (ja) 2014-02-05

Family

ID=39323721

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009541404A Expired - Fee Related JP5406725B2 (ja) 2006-12-14 2007-12-14 タンパク質キナーゼ阻害剤として有用な化合物

Country Status (12)

Country Link
US (2) US8129387B2 (OSRAM)
EP (1) EP2102210B1 (OSRAM)
JP (1) JP5406725B2 (OSRAM)
CN (1) CN101646671A (OSRAM)
AT (1) ATE497961T1 (OSRAM)
AU (1) AU2007334379B2 (OSRAM)
CA (1) CA2672612A1 (OSRAM)
DE (1) DE602007012473D1 (OSRAM)
ES (1) ES2359467T3 (OSRAM)
MX (1) MX2009006345A (OSRAM)
NZ (1) NZ577638A (OSRAM)
WO (1) WO2008076392A2 (OSRAM)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ601687A (en) 2006-01-17 2014-03-28 Vertex Pharma Azaindoles useful as inhibitors of janus kinases
WO2009103010A2 (en) * 2008-02-13 2009-08-20 Elan Pharmaceuticals, Inc. Alpha-synuclein kinase
KR20110039278A (ko) 2008-06-23 2011-04-15 버텍스 파마슈티칼스 인코포레이티드 단백질 키나제 억제제
CN102076691A (zh) 2008-06-23 2011-05-25 维泰克斯制药公司 蛋白激酶抑制剂
US20100075973A1 (en) * 2008-08-28 2010-03-25 Takeda Pharmaceutical Company Limited Polo-like kinase inhibitors
AU2010262905B2 (en) 2009-06-17 2015-04-16 Vertex Pharmaceuticals Incorporated Inhibitors of influenza viruses replication
EP2516441B1 (en) 2009-12-23 2015-01-21 Elan Pharmaceuticals Inc. Pteridinones as inhibitors of polo-like kinase
EP2661268A2 (en) 2010-10-08 2013-11-13 Elan Pharmaceuticals Inc. Inhibitors of polo-like kinase
KR20140014110A (ko) 2010-12-16 2014-02-05 버텍스 파마슈티칼스 인코포레이티드 인플루엔자 바이러스 복제의 억제제
WO2013006634A2 (en) 2011-07-05 2013-01-10 Vertex Pharmaceuticals Incorporated Processes and intermediates for producing azaindoles
UA118010C2 (uk) 2011-08-01 2018-11-12 Вертекс Фармасьютікалз Інкорпорейтед Інгібітори реплікації вірусів грипу
CN105658650B (zh) * 2013-06-24 2019-01-08 默克专利有限公司 用作卵泡刺激素受体调节剂的咪唑化合物及其用途
ES2741444T3 (es) 2013-11-13 2020-02-11 Vertex Pharma Inhibidores de la replicación de virus de la gripe
EP3068782B1 (en) 2013-11-13 2018-05-23 Vertex Pharmaceuticals Incorporated Methods of preparing inhibitors of influenza viruses replication
US9840503B2 (en) 2015-05-11 2017-12-12 Incyte Corporation Heterocyclic compounds and uses thereof
WO2016183120A1 (en) 2015-05-13 2016-11-17 Vertex Pharmaceuticals Incorporated Inhibitors of influenza viruses replication
WO2016183116A1 (en) 2015-05-13 2016-11-17 Vertex Pharmaceuticals Incorporated Methods of preparing inhibitors of influenza viruses replication
WO2017027717A1 (en) 2015-08-12 2017-02-16 Incyte Corporation Bicyclic fused pyrimidine compounds as tam inhibitors
US10053465B2 (en) 2015-08-26 2018-08-21 Incyte Corporation Pyrrolopyrimidine derivatives as TAM inhibitors
WO2017172596A1 (en) 2016-03-28 2017-10-05 Incyte Corporation Pyrrolotriazine compounds as tam inhibitors
CA3077308A1 (en) 2017-09-27 2019-04-04 Incyte Corporation Salts of pyrrolotriazine derivatives useful as tam inhibitors
PL3813800T3 (pl) 2018-06-29 2025-08-18 Incyte Corporation Formulacje inhibitora axl/mer
CN111217815B (zh) * 2018-11-27 2021-06-18 沈阳药科大学 含有喋啶酮骨架的化合物及其制备方法和应用
AU2021230385A1 (en) 2020-03-06 2022-09-22 Incyte Corporation Combination therapy comprising AXL/MER and PD-1/PD-L1 inhibitors

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999045009A1 (en) 1998-03-04 1999-09-10 Bristol-Myers Squibb Company Heterocyclo-substituted imidazopyrazine protein tyrosine kinase inhibitors
KR100983462B1 (ko) * 2003-02-26 2010-09-27 베링거 잉겔하임 파르마 게엠베하 운트 코 카게 디하이드로프테리디논, 이의 제조방법 및 약제로서의 이의 용도
US7728134B2 (en) 2004-08-14 2010-06-01 Boehringer Ingelheim International Gmbh Hydrates and polymorphs of 4[[(7R)-8-cyclopentyl-7-ethyl-5,6,7,8-tetrahydro-5-methyl-6-oxo-2-pteridinyl]amino]-3-methoxy-N-(1-methyl-4-piperidinyl)-benzamide, process for their manufacture and their use as medicament
US20060074088A1 (en) 2004-08-14 2006-04-06 Boehringer Ingelheim International Gmbh Dihydropteridinones for the treatment of cancer diseases
US20060058311A1 (en) 2004-08-14 2006-03-16 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation
EA200900593A1 (ru) 2006-10-25 2010-06-30 Хрома Терапьютикс Лтд. Производные птеридина как ингибиторы polo-подобной киназы, применяющиеся при лечении рака
GB0621203D0 (en) 2006-10-25 2006-12-06 Chroma Therapeutics Ltd PLK inhibitors
AU2008236872B2 (en) 2007-04-05 2013-01-17 Alla Chem, Llc Substituted 2,3,4,5-tetrahydro-1h-pyrido[4,3-b]indoles, methods for the production and use thereof
RU2339637C1 (ru) 2007-04-05 2008-11-27 Андрей Александрович Иващенко Блокаторы гистаминного рецептора для фармацевтических композиций, обладающих противоаллергическим и аутоиммунным действием

Also Published As

Publication number Publication date
CN101646671A (zh) 2010-02-10
ES2359467T3 (es) 2011-05-23
NZ577638A (en) 2012-03-30
EP2102210A2 (en) 2009-09-23
AU2007334379A1 (en) 2008-06-26
CA2672612A1 (en) 2008-06-26
US8129387B2 (en) 2012-03-06
EP2102210B1 (en) 2011-02-09
DE602007012473D1 (de) 2011-03-24
MX2009006345A (es) 2009-06-23
US20100099686A1 (en) 2010-04-22
JP2010513285A (ja) 2010-04-30
US20120122879A1 (en) 2012-05-17
ATE497961T1 (de) 2011-02-15
AU2007334379B2 (en) 2013-04-18
US8557818B2 (en) 2013-10-15
WO2008076392A3 (en) 2008-08-07
WO2008076392A2 (en) 2008-06-26

Similar Documents

Publication Publication Date Title
JP5406725B2 (ja) タンパク質キナーゼ阻害剤として有用な化合物
JP5313875B2 (ja) 増殖性疾患の処置のためのタンパク質キナーゼｐｌｋ１の阻害剤として有用な４，５−ジヒドロ−［１，２，４］トリアゾロ［４，３−ｆ］プテリジン
JP5634990B2 (ja) タンパク質キナーゼ阻害剤
JP5380447B2 (ja) 増殖性疾患の処置のための、ヒトタンパク質キナーゼｐｌｋ１ないしｐｌｋ４の阻害剤としての４−（９−（３，３−ジフルオロシクロペンチル）−５，７，７−トリメチル−６−オキソ−６，７，８，９−テトラヒドロ−５ｈ−ピリミド［４，５−ｂ［１，４］ジアゼパン−２−イルアミノ］−３−メトキシベンザミド誘導体
JP5869338B2 (ja) タンパク質キナーゼ阻害剤
JP2009533452A (ja) タンパク質キナーゼの阻害剤として有用なチオフェン−カルボキサミド
JP2009538309A (ja) プロテインキナーゼのインヒビターとして有用なチオフェンカルボキサミド
JP2009528991A (ja) プロテインキナーゼの阻害剤として有用なピロロ（３，２−ｃ）ピリジン
JP2009536617A (ja) タンパク質キナーゼの阻害剤として有用なチアゾール、イミダゾール、およびピラゾール
US8481578B2 (en) Thiophene-carboxamides useful as inhibitors of protein kinases
JP2009523822A (ja) プロテインキナーゼのインヒビターとして有用なチオフェン−カルボキサミド
US7838517B2 (en) Compounds useful as protein kinase inhibitors
JP2009515984A (ja) キナーゼ阻害剤として有用なアザインダゾール
HK1130788A (en) Thiophene-carboxamides useful as inhibitors of protein kinases
HK1141512A (en) Compounds useful as protein kinase inhibitors
HK1137013A (en) Compounds useful as protein kinase inhibitors
HK1134285A (en) Thiophene-carboxamides useful as inhibitors or protein kinases

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20101213

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110222

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130219

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130514

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130611

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130904

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20131008

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20131101

LAPS Cancellation because of no payment of annual fees